Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of "Buy" from Analysts

Key Points

• Kiniksa Pharmaceuticals International has received a consensus rating of "Buy" from six analysts, with an average 12-month price target of $41.17.
• Insider sales have been significant, with insiders selling 544,971 shares valued at $18.2 million in the last ninety days, indicating a potential decrease in confidence among company leadership.
• The company reported strong quarterly earnings, beating estimates with a net revenue of $156.8 million and earnings per share of $0.23, surpassing the projected $0.18.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) has received an average recommendation of "Buy" from the six analysts that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $41.1667.

Several equities research analysts have commented on KNSA shares. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 7th. Wedbush restated an "outperform" rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 9th. Finally, Jefferies Financial Group increased their price objective on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research report on Tuesday, July 29th.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director Thomas Malley sold 78,233 shares of the company's stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the transaction, the director directly owned 12,546 shares in the company, valued at $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John F. Paolini sold 29,325 shares of the company's stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $32.55, for a total value of $954,528.75. Following the transaction, the insider owned 57,403 shares in the company, valued at $1,868,467.65. This trade represents a 33.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 544,971 shares of company stock valued at $18,227,065 over the last ninety days. 53.48% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Northern Trust Corp increased its position in shares of Kiniksa Pharmaceuticals International by 11.1% during the fourth quarter. Northern Trust Corp now owns 283,599 shares of the company's stock worth $5,610,000 after acquiring an additional 28,393 shares during the period. Bank of America Corp DE grew its holdings in shares of Kiniksa Pharmaceuticals International by 2.2% during the fourth quarter. Bank of America Corp DE now owns 215,772 shares of the company's stock worth $4,268,000 after purchasing an additional 4,654 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth about $256,000. Deutsche Bank AG grew its holdings in shares of Kiniksa Pharmaceuticals International by 77.3% during the fourth quarter. Deutsche Bank AG now owns 142,397 shares of the company's stock worth $2,817,000 after purchasing an additional 62,083 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth about $61,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Stock Up 0.2%

Shares of Kiniksa Pharmaceuticals International stock opened at $37.10 on Monday. Kiniksa Pharmaceuticals International has a twelve month low of $17.82 and a twelve month high of $37.34. The business has a 50-day moving average price of $31.86 and a 200 day moving average price of $27.18. The firm has a market cap of $2.75 billion, a PE ratio of 927.73 and a beta of 0.20.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%.The firm had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.